Literature summary for 2.1.1.370 extracted from

Zhou, B.; Wang, J.; Lee, S.Y.; Xiong, J.; Bhanu, N.; Guo, Q.; Ma, P.; Sun, Y.; Rao, R.C.; Garcia, B.A.; Hess, J.L.; Dou, Y.
PRDM16 suppresses MLL1r leukemia via intrinsic histone methyltransferase activity (2016), Mol. Cell, 62, 222-236 .

Search for more literature for 2.1.1.370

Protein Variants

Protein Variants	Comment	Organism
C113F/V115G	loss of histone methyltransferase activity	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q9HAZ2	cf. EC 2.1.1.367	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
additional information	PRDM16 is able to mono- and di-methylate H3K4 in nucleosomes. No tri-methylation of H3K4 or methylation of other lysine residues of H3 is detected	Homo sapiens	?	-	-
S-adenosyl-L-methionine + a [histone H3]-L-lysine4	-	Homo sapiens	S-adenosyl-L-homocysteine + a [histone H3]-N6-methyl-L-lysine4	-	?
S-adenosyl-L-methionine + a [histone H3]-N6-methyl-L-lysine4	-	Homo sapiens	S-adenosyl-L-homocysteine + a [histone H3]-N6,N6-dimethyl-L-lysine4	-	?

Synonyms

Synonyms	Comment	Organism
MEL	-	Homo sapiens
PFM13	-	Homo sapiens
PRDM16	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	PRDM16 is a histone H3 K9 methyltransferase on chromatin. Mutation in the N-terminal PR-domain of PRDM16 completely abolishes the intrinsic enzymatic activity of PRDM16. The methyltransferase activity of PRDM16 is required for specific suppression of mixed lineage leukemia leukemogenesis both in vitro and in vivo. PRDM16 directly activates the SNAG family transcription factor GFI1b, which in turn down regulates the HOXA gene cluster. Knockdown GFI1b represses PRDM16-mediated tumor suppression while GFI1b overexpression mimics PRDM16 overexpression. Silencing PRDM16 by DNA methylation is concomitant with mixed lineage leukemia MLL-AF9 induced leukemic transformation	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)